About

Press Releases

2014

07 August 2014
GI Dynamics to Present at the 34th Annual Canaccord Genuity Growth Conference

31 July 2014
Appendix 4C Quarterly Report Quarter ended 30 June 2014

30 July 2014
GI Dynamics Announces Launch of EndoBarrier® Therapy Clinical Utility Study in France

21 July 2014
GI Dynamics to Hold Briefing Call and Webcast on Financial Results for Second Quarter 2014

01 July 2014
GI Dynamics Announces Departure of Chief Commercial Officer

16 June 2014
Data Presented at ADA Show the Effects of GI Dynamics’ EndoBarrier® Therapy on Glycemic Control and Reducing Diabetes Medication in Patients with Type 2 Diabetes and Obesity

09 June 2014
GI Dynamics Announces EndoBarrier® Data to be Presented at The American Diabetes Association's 74th Scientific Sessions

15 May 2014
GI Dynamics Announces New Findings that Show Elimination of and Reduced Reliance on Insulin by Patients Treated with EndoBarrier® Therapy

15 May 2014
2014 Annual Meeting of Stockholders Access for Participants by Webcast and Conference Call

12 May 2014
GI Dynamics Further Expands Availability of EndoBarrier® Therapy in Australia through Two Additional Centres

05 May 2014
GI Dynamics Announces New EndoBarrier® Data from Research with GlaxoSmithKline Presented during Digestive Disease Week

02 May 2014
GI Dynamics, Inc. Announces Completion of A$34.3 Million Private Placement

01 May 2014
GI Dynamics to Present at the Deutsche Bank 39th Annual Health Care Conference

28 April 2014
Appendix 4C Quarterly Report Quarter ended 31 March 2014

28 April 2014
GI Dynamics Announces New EndoBarrier® Data to be Presented at Upcoming Medical Meetings

14 April 2014
GI Dynamics to Hold Briefing Call and Webcast on Financial Results for First Quarter 2014

07 April 2014
EndoBarrier® Therapy Receives Reimbursement Coverage in Israel

01 April 2014
GI Dynamics Expands Availability of EndoBarrier® Therapy in Australia in Two Additional Cities

27 March 2014
GI Dynamics Secures Preliminary Reimbursement Coverage for EndoBarrier® Therapy in the Netherlands

07 March 2014
S&P Dow Jones Indices Announces March 2014 Quarterly Rebalance of the S&P/ASX Indices; GI Dynamics to be Included in All Ordinaries Index

24 February 2014
GI Dynamics to Present at Cowen & Company 34th Annual Health Care Conference

03 February 2014
GI Dynamics Announces Expanded Reimbursement Coverage in Germany

31 January 2014
Appendix 4C Quarterly Report Quarter ended 31 December 2013

21 January 2014
GI Dynamics to Hold Briefing Call and Webcast on Financial Results for Fourth Quarter 2013

2013

03 December 2013
Results of New Meta-Analysis Further Demonstrate Safety Profile and Robust Efficacy of EndoBarrier® Therapy in Patients with Type 2 Diabetes and Obesity

25 November 2013
GI Dynamics Announces EndoBarrier® Therapy Data to be Presented at International Diabetes Foundation World Diabetes Conference

12 November 2013
GI Dynamics Announces EndoBarrier® Therapy Data to be Presented at Obesity Week

09 October 2013
GI Dynamics to Participate in Diabetes Treatment Panel Discussion at Cleveland Clinic’s 11th Annual Medical Innovation Summit

01 October 2013
EndoBarrier® Therapy Receives OPS Codes in Germany and Switzerland

25 September 2013
Clinical Research Findings Presented at European Diabetes Meeting Reinforce Efficacy of EndoBarrier® Therapy in Treatment of Type 2 Diabetes

17 September 2013
GI Dynamics Reports on Recent EndoBarrier® Therapy Clinical Highlights and Activities

12 September 2013
GI Dynamics, Inc. Provides Update on Progress of the ENDO Trial

10 September 2013
Association of British Clinical Diabetologists Funds and Initiates National Health Service Supported Study of EndoBarrier® Therapy in the United Kingdom

08 August 2013
GI Dynamics to Present at Canaccord Genuity 33rd Annual Growth Conference

02 July 2013
GI Dynamics, Inc. Announces Completion of A$57.5 Million Private Placement And Launch of Share Purchase Plan

26 June 2013
GI Dynamics, Inc. Appoints Distributor for the Middle East

18 June 2013
French Government Approves Two-Year Clinical Utility Study of EndoBarrier® Therapy

17 June 2013
GI Dynamics Announces New Commercial Centres Offering EndoBarrier® Therapy in the European Union

13 May 2013
2013 Annual General Meeting Access for Participants by Webcast and Conference Call

30 April 2013
GI Dynamics, Inc. Appoints David Maggs, M.D. as Chief Medical Officer

25 April 2013
GI Dynamics, Inc. Reports on Progress of the ENDO Trial

18 March 2013
EndoBarrier® Therapy Named Product of the Year by BioSpectrum Asia

06 March 2013
GI Dynamics Announces Agreement with CMS Medical for Distribution of EndoBarrier® Therapy in Brazil

26 February 2013
GI Dynamics Announces Commercial Availability of EndoBarrier® Therapy in Israel for the Treatment of Type 2 Diabetes and/or Obesity

26 February 2013
GI Dynamics to Present at the Cowen & Co. 33rd Annual Healthcare Conference

19 February 2013
GI Dynamics to Hold Briefing Call and Webcast on Financial Results for 2012

31 January 2013
Data Show EndoBarrier® Therapy Demonstrates Glycemic Control in People with Type 2 Diabetes Who are Mildly Obese

15 January 2013
GI Dynamics, Inc. Initiates U.S. Pivotal Clinical Trial of EndoBarrier®

09 January 2013
GI Dynamics Announces Resolution of Litigation with Gore

04 January 2013
GI Dynamics Announces Research Collaborations with GlaxoSmithKline and Medtronic

2012

06 November 2012
GI Dynamics to Present at Upcoming Investor Conferences

30 October 2012
GI Dynamics, Inc. Receives FDA Approval to Commence Pivotal Clinical Trial of EndoBarrier®

22 October 2012
GI Dynamics Announces First Clinical Study to Demonstrate Improvement in Weight Loss and Co-morbid Conditions Following EndoBarrier® Re-implantation

22 October 2012
GI Dynamics Announces New Insights into EndoBarrier® Therapy’s Influence on Key Hormones Affecting Satiety and Blood Sugar Control

22 October 2012
GI Dynamics to Hold Briefing Call and Webcast on Financial Results for Third Quarter 2012

02 October 2012
Study Shows EndoBarrier® Therapy Offers Improved and Sustained Glycemic Control in People with Type 2 Diabetes Who Are Overweight

24 September 2012
St. Vincent’s Clinic and Macquarie University Hospital in Sydney Incorporate EndoBarrier® Therapy into Type 2 Diabetes and Obesity Treatment Options

23 August 2012
GI Dynamics, Inc. Announces FDA Conditional Approval for Pivotal Clinical Trial of the EndoBarrier®

23 July 2012
GI Dynamics to Hold Briefing Call and Webcast on Financial Results for Second Quarter 2012

17 July 2012
GI Dynamics, Inc. Announces Further Strengthening of Commercial Foundation for EndoBarrier® Therapy and Progress with New Centers in Key Markets

22 June 2012
Study Presented at American Society for Metabolic & Bariatric Surgery Meeting Demonstrates Efficacy of EndoBarrier® Therapy in Treating Overweight and Mildly Obese Type 2 Diabetes Patients

11 June 2012
Data on GI Dynamics’ EndoBarrier® Therapy Presented at the ADA 72nd Scientific Sessions

01 June 2012
GI Dynamics to Present at the Jefferies 2012 Global Healthcare Conference

31 May 2012
Summary Judgment Ruling on Counterclaims in Gore vs. GI Dynamics Lawsuit

14 May 2012
EndoBarrier® Therapy to be Featured at Digestive Disease Week 2012

01 May 2012
EndoBarrier® Therapy Data Published in Annals of Surgery

27 April 2012
GI Dynamics Announces New Data Demonstrating Feasibility of EndoBarrier® Reimplantation

19 April 2012
GI Dynamics Announces First Cases of EndoBarrier® Therapy in Australia

04 April 2012
GI Dynamics, Inc. Expands Global Commercial Team

07 March 2012
GI Dynamics Designates First EndoBarrier® Center of Excellence in Australia

28 February 2012
GI Dynamics Announces Full-Year 2011 Financial Results

27 February 2012
GI Dynamics to Present at Upcoming Investor Conferences

23 February 2012
GI Dynamics to Hold Briefing Call and Webcast on Financial Results for 2011

09 February 2012
GI Dynamics, Inc. Designates National Obesity Surgery Centre as Center of Excellence in the United Kingdom

05 January 2012
GI Dynamics, Inc. to Present at the 30th Annual J.P. Morgan Global Healthcare Conference

04 January 2012
GI Dynamics, Inc. Announces Commercial Availability of the EndoBarrier® for the Treatment of Type 2 Diabetes and/or Obesity in the Netherlands

2011

14 December 2011
GI Dynamics, Inc. Expands Availability of the EndoBarrier® Through Two New Centers of Excellence in Germany

29 November 2011
GI Dynamics, Inc. Appoints Mark Twyman as Its Chief Commercial Officer

29 November 2011
GI Dynamics to Present at Canaccord Genuity 6th Annual Cardiovascular, Aesthetics & Metabolic Disorders Conference

09 November 2011
GI Dynamics to Present at Lazard Capital Markets 8th Annual Healthcare Conference

28 October 2011
Appendix 4C Quarterly Report

03 October 2011
GI Dynamics, Inc. Announces Data Demonstrating Blood Sugar Control and Weight Loss Benefits of EndoBarrier Treatment Beyond Implant Period

21 September 2011
GI Dynamics, Inc. Launches EndoBarrier® in Austria for the Treatment of Type 2 Diabetes and Obesity

16 September 2011
GI Dynamics to Present at UBS Global Life Sciences Conference

15 September 2011
New Data Presented at EASD Reveals EndoBarrier® Effect on GI Hormones Key to Improving Glycemic Control

07 September 2011
GI Dynamics Commences Trading on the ASX Following Successful A$80 Million Offers

23 August 2011
GI Dynamics Welcomes the Addition of Three U.S. and Australian Based Directors to its Board

25 July 2011
GI Dynamics Receives Australian TGA Approval For the EndoBarrier® Gastrointestinal Liner for the Treatment of Type 2 Diabetes and Obesity

10 May 2011
Data on GI Dynamics’ EndoBarrier® for Type 2 Diabetes and Obesity Highlighted at Digestive Disease Week 2011

29 March 2011
New Data Show EndoBarrier® Triggers Beneficial Hormone Effects; Helps Patients Achieve Rapid Glycemic Control and Weight Loss while Reducing Heart Disease Risk Factors

2010

29 November 2010
GI Dynamics to Present at Upcoming Investment Conferences

01 November 2010
GI Dynamics Shares Insights on Novel Therapies in Type 2 Diabetes at the Cleveland Clinic 2010 Medical Innovation Summit

15 October 2010
GI Dynamics Receives European CE Mark Approval for 12 Months of EndoBarrier™ Treatment of Type 2 Diabetes and Obesity; Announces U.K. Launch

07 September 2010
GI Dynamics Announces New Data Showing Significant Weight Loss, Cardiovascular and Metabolic Improvements Following 12 Months of EndoBarrier™ Treatment

01 September 2010
GI Dynamics Announces Distribution Agreement with Elemental Healthcare for the EndoBarrier™ Gastrointestinal Liner

19 August 2010
GI Dynamics Announces Key Executive Appointments in Preparation for European Launch of EndoBarrier™ Gastrointestinal Liner

03 May 2010
GI Dynamics’ EndoBarrier™ Gastrointestinal Liner Demonstrates Improvements in Blood Sugar Control and Facilitates Weight Loss in People Living with Type 2 Diabetes

03 March 2010
Study Demonstrates People Living with Type 2 Diabetes and Obesity Can be Successfully Treated with GI Dynamics’ EndoBarrier™ Gastrointestinal Liner for 12 Months

22 February 2010
Atrium Medical Center Parkstad and GI Dynamics Initiate Clinical Trial of EndoBarrier™ Gastrointestinal Liner for the Treatment of Type 2 Diabetes

10 February 2010
GI Dynamics’ EndoBarrier™ Gastrointestinal Liner to be Highlighted at Upcoming Cleveland Clinic Conference

07 January 2010
GI Dynamics Receives Strategic Investment from Medtronic, Inc

2009

22 December 2009
GI Dynamics Receives European CE Mark Approval for the EndoBarrier™ Gastrointestinal Liner System for the Treatment of Type 2 Diabetes and Obesity

23 November 2009
Interim Data from a Clinical Trial Evaluating GI Dynamics’ EndoBarrier™ Gastrointestinal Liner in Patients with Type 2 Diabetes Presented at GASTRO 2009

11 November 2009
GI Dynamics’ EndoBarrier ™ Gastrointestinal Liner Demonstrates Significant HbA1c Reduction in Obese People Living with Type 2 Diabetes

27 October 2009
GI Dynamics’ EndoBarrier ™ Gastrointestinal Liner Demonstrates Safety and Efficacy in Pre-surgical Weight Loss

26 August 2009
Data from a Clinical Study Evaluating GI Dynamics’ EndoBarrier to be Presented at IFSO

26 June 2009
Novel Non-Surgical Therapy Dramatically Increases Weight Loss in Obese Patients; Results from Pilot Clinical Study Presented at ASMBS

18 June 2009
New Clinical Data on GI Dynamics’ EndoBarrier™ Flow Restrictor to be Presented at the 26th Annual Meeting of the American Society for Metabolic and Bariatric Surgery

03 June 2009
GI Dynamics’ EndoBarrier™ Gastrointestinal Liner to be Highlighted at Several Prominent International Diabetes and Obesity Meetings

25 April 2009
Weight Loss Data for EndoBarrier™ Technology Platform Presented at the Society of American Gastrointestinal and Endoscopic Surgeons 2009 Annual Meeting (SAGES)

20 April 2009
New Data on GI Dynamics’ EndoBarrier™ Technology Platform to be Presented at Upcoming Medical Meetings

19 February 2009
GI Dynamics Closes an Additional $15 Million in Series C Financing

07 January 2009
GI Dynamics Receives ISO Certification and European CE Mark Approval for the EndoBarrier™ Gastrointestinal Liner System

2008

18 November 2008
New Data in Journal Obesity Demonstrate that a Noninvasive, Removable Medical Device Results in Substantial Weight Loss and Glucose Normalization in a Preclinical Model of Obesity

26 September 2008
GI Dynamics Announces Promising Multi-Center Safety and Efficacy Data of EndoBarrier™ Gastrointestinal Liner for Pre-Surgical Weight Loss

19 September 2008
GI Dynamics to Present Data from Clinical Weight Loss Study of EndoBarrier™ Gastrointestinal Liner in Morbidly Obese Patients at the International Federation for Surgery of Obesity and Metabolic Disorders (IFSO) 13th World Congress

16 September 2008
GI Dynamics Announces Data Demonstrating Immediate and Sustained Reduction in HbA1c in Patients with Type 2 Diabetes Using EndoBarrier™ Gastrointestinal Liner

09 September 2008
Data from Clinical Trial of EndoBarrier™ Gastrointestinal Liner in Patients with Type 2 Diabetes to be Presented at the First World Congress on Interventional Therapies for Type 2 Diabetes in New York